Intrauterine contraception: an update

References

• Barbosa I, Bakos O, Olsson S. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42: 51–66
   PubMed Web of Science ®Google Scholar
• Barrington J W, Bowen-Simpkins P. The levonorgestrel-releasing intrauterine system in the management of menorrhagia. British Journal of Obstetrics and Gynaecology 1997; 104: 614–616
   PubMedGoogle Scholar
• Bhathena R K, Guillebaud J. Contraception for the older woman: an update. Climacteric 2006; 9: 264–276
   PubMed Web of Science ®Google Scholar
• Chi I C. What we have learnt from recent IUD studies: a researcher's perspective. Contraception 1993; 48: 81–108
   PubMed Web of Science ®Google Scholar
• Dennis J, Hampton N. IUDs: which device. Journal of Family Planning and Reproductive Health Care 2002; 28: 61–68
   PubMedGoogle Scholar
• Farley T M, Rosenberg M J, Rowe P J, Chen J H, Meirik O. Intrauterine contraceptive devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785–788
   PubMed Web of Science ®Google Scholar
• FFPRHC. UK selected practice recommendations for contraceptive use. 2002, Available at: http://www.ffprhc.org.uk
   Google Scholar
• FFPRHC Guidance. The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. Journal of Family Planning and Reproductive Health Care 2004; 30: 99–109
   PubMedGoogle Scholar
• FFPRHC Guidance. The use of contraception outside the terms of the product licence. Journal of Family Planning and Reproductive Health Care 2005; 31: 225–242
   PubMedGoogle Scholar
• Grimes D A. Intrauterine device and upper genital tract infection. Lancet 2000; 356: 1013–1019
   PubMed Web of Science ®Google Scholar
• Guillebaud J. Intrauterine contraception. Contraception today6th ed, J Guillebaud. Informa Healthcare, London 2007; 98–123
   Google Scholar
• Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported. Contraception 2003; 67: 53–56
   PubMed Web of Science ®Google Scholar
• Haugan T, Skjeldestad F, Halvorsen L, Kahn H. A randomised trial on the clinical performance of Nova-T 380 and Gyne-T 380 Slimline copper IUDs. Contraception 2007; 75: 171–176
   PubMed Web of Science ®Google Scholar
• Hill D A, Weiss N S, Voigt L F, Beresford S A. Endometrial cancer in relation to intrauterine device use. International Journal of Cancer 1997; 70: 278–281
   PubMed Web of Science ®Google Scholar
• Hubacher D, Lara-Ricalder, Taylor D J, Guerra-Infante E, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. New England Journal of Medicine 2001; 345: 561–567
   PubMed Web of Science ®Google Scholar
• Koetsawang S, Rachawat D, Piya-Anant M. Outcome of pregnancy in the presence of an intrauterine device. Acta Obstetricia Gynecologica Scandinavica 1977; 56: 479–482
   PubMed Web of Science ®Google Scholar
• Masters T, Everett S. Intrauterine and barrier contraception (a practical review of recent developments). Current Obstetrics and Gynaecology 2005; 15: 31–37
   Google Scholar
• Mishell D R, Jr. Intrauterine devices: mechanisms of action, safety and efficacy. Contraception 1998; 58: 45S–53S
   PubMed Web of Science ®Google Scholar
• NICE. Clinical Guideline. Long-acting reversible contraception. National Institute for Health and Clinical Excellence. 2005
   Google Scholar
• Office for National Statistics. Contraception and Sexual Health, 2006/07. HMSO. Available at: http://www.statistics.gov.uk, London 2007
   Google Scholar
• Pakarinen P I, Lahteenmaki P, Lehtonen E. The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel. Human Reproduction 1998; 13: 1846–1853
   PubMed Web of Science ®Google Scholar
• Peterson H B, Xia Z, Hughes J M, Wilcox L S, Tylor L R, Trussell J. The risk of pregnancy after tubal sterilisation: findings from the US Collaborative Review of Sterilisation. American Journal of Obstetrics and Gynecology 1996; 174: 1161–1170
   PubMed Web of Science ®Google Scholar
• Population Report. New Attention to the IUD. John Hopkins School of Public Health. 2006; XXXIII: 1–27
   Google Scholar
• Sivin I, Stern J, Coutinho E, Mattos C E, Mahgoub S E, Diaz S. Long-term contraception with the LNG 20 mcg/day and the CuT 380Ag intrauterine devices: a five-year randomized study. Contraception 1990; 42: 361–378
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J, Coutinho E. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNG 20) and the copper T380 Ag IUDs. Contraception 1991; 44: 473–480
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 mg/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicentre study. Fertility and Sterility 1994; 61: 70–77
   PubMed Web of Science ®Google Scholar
• Standford J B, Mikolajczyk R T. Mechanisms of action of intrauterine devices: update and estimation of postfertilisation effects. American Journal of Obstetrics and Gynecology 2002; 187: 1699–1708
   PubMed Web of Science ®Google Scholar
• UK Medical Eligibility Criteria (UKMEC) for Contraceptive Use 2005/2006. The Faculty of Family Planning and Reproductive Health Care. 2006; 73–88, Available athttp://www.ffprhc.org.uk
   Google Scholar
• United Nations Development Programme United Nations Population Fund World Health Organisation and World Bank Special Programme of Research. A randomized multicentre trial of the Multiload Cu375 and TCu 380A IUDs in parous women: three year results. Contraception 1994; 49: 543–549
   PubMed Web of Science ®Google Scholar
• United Nations Development Programme United Nations Population Fund World Health Organisation and World Bank Special Programme of Research. Long-term reversible contraception: Twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56: 341–352
   PubMed Web of Science ®Google Scholar
• WHO. Mechanism of action, safety and efficacy of intrauterine devices. Technical Report. 1987; 1–91.
   Google Scholar
• WHO. Medical eligibility criteria for contraceptive use. WHO, Geneva 2004
   Google Scholar
• WHO. Selected practice recommendations for contraceptive use. 2nd ed. WHO, Geneva 2005
   Google Scholar
• Zhou L, Harrison-Woolrych M, Coulter D M. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiology and Drug Safety 2003; 12: 371–377
   PubMed Web of Science ®Google Scholar